Could a Cottonseed-Derived drug help beat Chemo-Resistant colon cancer?
NCT ID NCT07337551
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests a combination of gossypol acetate (a drug from cottonseed), bevacizumab, and FOLFIRI chemotherapy in 20 people with metastatic colorectal cancer that has a TP53 mutation and is LRPPRC-positive. The goal is to see if this mix can shrink tumors or slow the cancer after first-line treatment has failed. The study is based on lab findings that gossypol acetate may help reverse drug resistance.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gossypol acetate combined with bevacizumab and FOLFIRI (chemotherapy)
What this could lead to
If it works, this could offer a new second-line treatment option for people with a specific type of metastatic colorectal cancer that has stopped responding to first-line therapy.
What could go wrong
This is a very early, small study with only 20 participants and no comparison group. The combination may not work better than existing options, and side effects from the drugs could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PATIENTS WITH METASTATIC COLORECTAL CANCER WHO WERE TP53-MUTANT AND LRPPRC-POSITIVE AND HAD PREVIOUSLY FAILED PRIOR FIRST-LINE TREATMENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••